A randomized controlled trial of prison-initiated buprenorphine: Prison outcomes and community treatment entry

Simple item page
dc.contributor.authorVocci, Frank J.
dc.contributor.authorO’Grady, Kevin E.
dc.contributor.authorFitzgerald, Terrence T.
dc.contributor.authorSchwartz, Robert P.
dc.contributor.authorKinlock, Timothy W.
dc.contributor.authorGordon, Michael S.
dc.contributor.departmentSchool of Humanities and Social Sciences
dc.date.accessioned2018-05-22T18:32:01Z
dc.date.available2018-05-22T18:32:01Z
dc.date.issued2014-09-01
dc.description.abstractBackground Buprenorphine is a promising treatment for heroin addiction. However, little is known regarding its provision to pre-release prisoners with heroin dependence histories who were not opioid-tolerant, the relative effectiveness of the post-release setting in which it is provided, and gender differences in treatment outcome in this population. Methods This is the first randomized clinical trial of prison-initiated buprenorphine provided to male and female inmates in the US who were previously heroin-dependent prior to incarceration. A total of 211 participants with 3–9 months remaining in prison were randomized to one of four conditions formed by crossing In-Prison Treatment Condition (received buprenorphine vs. counseling only) and Post-release Service Setting (at an opioid treatment center vs. a community health center). Outcome measures were: entered prison treatment; completed prison treatment; and entered community treatment 10 days post-release. Results There was a significant main effect (p=.006) for entering prison treatment favoring the In-Prison buprenorphine Treatment Condition (99.0% vs. 80.4%). Regarding completing prison treatment, the only significant effect was Gender, with women significantly (p<.001) more likely to complete than men (85.7% vs. 52.7%). There was a significant main effect (p=.012) for community treatment entry, favoring the In-Prison buprenorphine Treatment Condition (47.5% vs. 33.7%). Conclusions Buprenorphine appears feasible and acceptable to prisoners who were not opioid-tolerant and can facilitate community treatment entry. However, concerns remain with in-prison treatment termination due to attempted diversion of medication.en_US
dc.description.urihttps://ezproxy.stevenson.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=edselp&AN=S037687161400893X&site=eds-live&scope=siteen_US
dc.identifierdoi:10.13016/M23N20H51
dc.identifier.citationGordon, M. S., Kinlock, T. W., Schwartz, R. P., Fitzgerald, T. T., O’Grady, K. E., & Vocci, F. J. (2014). A randomized controlled trial of prison-initiated buprenorphine: Prison outcomes and community treatment entry. Drug And Alcohol Dependence, 14233-40. doi:10.1016/j.drugalcdep.2014.05.011en_US
dc.identifier.issn0376-8716
dc.language.isoen_USen_US
dc.titleA randomized controlled trial of prison-initiated buprenorphine: Prison outcomes and community treatment entryen_US
dc.typeTexten_US

Files

License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Stevenson University Faculty and Staff Works